keine Finanzberatung

DXCM · DexCom, Inc.

Continuous glucose monitor (CGM) maker for diabetes care

Risiko 5/10 · MODERATE RISK · priced-for-growth medtech · $87.90 ▼ 2.02%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $87.90
  • Market cap $33.2B
  • P/E (ttm) 34.74
  • Div yield none
  • 52-wk range $54.11 – $92.59
  • Index rank #150 / #99

Wichtigste Risiken

  • Multiple compresses on any growth slowdown (Shareholders) — HIGH
  • Abbott's Libre wins the price-and-share war (Shareholders) — MED
  • GLP-1s slow diabetes progression over the long term (Shareholders) — LOW
  • Reimbursement and coverage changes for CGM (Shareholders) — LOW

Fazit

The business is executing; the stock already knows it — at this multiple, every quarter has to beat.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.